Equities

Magforce AG

Magforce AG

Actions
  • Price (EUR)0.0014
  • Today's Change0.000 / -12.50%
  • Shares traded0.00
  • 1 Year change+600.00%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024 07:16 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Magforce AG is a Germany-based company engaged in the provision of nanotechnology solutions for health sector. Its non-invasive technology uses magnetic nanoparticles to combat tumors, without harmful effect on the healthy tissues. The Company's range of treatment products includes NanoTherm Therapie for treating tumors locally; NanoTherm, a fluid containing ferrous oxide molecules that penetrate deeply into the tumor tissues and reacting to the presence of a magnetic field; NanoActivator, which are iron oxide nanoparticles for tumors in all areas of the body, and NanoPlan, a software platform that facilitates therapy planning and adjusts proper temperatures for the treatment and and the necessary magnetic field strength. As of December 31, 2011, Nanostart AG held a 49.6%-stake in the Company.

  • Revenue in EUR (TTM)351.98k
  • Net income in EUR-10.57m
  • Incorporated2005
  • Employees69.00
  • Location
    Magforce AGMax-Planck-Strasse 3BERLIN 12489GermanyDEU
  • Phone+49 303083800
  • Fax+49 3 030838099
  • Websitehttps://www.magforce.com/
More ▼

Institutional shareholders

0.37%Per cent of shares held by top holders
HolderShares% Held
Ruffer LLPas of 30 Nov 2023112.03k0.37%
Baring Asset Management Ltd.as of 31 Oct 20220.000.00%
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.